Omitting Routine Prophylactic Pegfilgrastim During Paclitaxel Portion Of Treatment Appears Safe And Feasible For Certain Patients With Breast Cancer
Healio (7/13, Southall) reports researchers found “omitting routine prophylactic pegfilgrastim during the paclitaxel portion of treatment appeared safe and feasible for certain patients with breast cancer.” The “researchers found no causal relationship between omission of pegfilgrastim and noncompletion of paclitaxel.” Some “common reasons for dose-reduction or delays in treatment were nonhematologic. Febrile neutropenia occurred in one patient who was able to complete paclitaxel on time.” The findings were published in Journal of Clinical Oncology.